Nemeth Balazs, Kiss Istvan, Jencsik Timea, Peter Ivan, Kreska Zita, Koszegi Tamas, Miseta Attila, Kustan Peter, Boncz Imre, Laczo Andrea, Ajtay Zeno
Department of Public Health Medicine, Medical School, University of Pecs, Pecs, Hungary
Zsigmondy Vilmos SPA Hospital, Harkany, Hungary.
In Vivo. 2017 May-Jun;31(3):425-428. doi: 10.21873/invivo.11077.
To study the effect of carbon dioxide (CO) therapy on the nitric oxide (NO) pathway by monitoring plasma asymmetric dimethylarginine (ADMA) concentrations.
Forty-seven hypertensive patients who underwent transcutaneous CO therapy were enrolled. Thirty healthy individuals were recruited for the control group. Blood samples were taken one hour before, as well as one hour, 24 hours and 3 weeks after the first CO treatment. Controls did not undergo CO treatment. Plasma ADMA levels were measured by ELISA.
ADMA levels decreased significantly one hour after the first CO2 treatment compared to the baseline concentrations (p=0.003). Significantly greater reduction was found among patients in whom angiotensin converting enzyme inhibitors (ACEIs) were administered (p=0.019).
The short- and long-term decrease of ADMA levels suggests that CO is not only a vasodilator, but also has a beneficial effect on the NO pathway. ACE inhibition seems to enhance the effect of CO treatment.
通过监测血浆不对称二甲基精氨酸（ADMA）浓度，研究二氧化碳（CO）疗法对一氧化氮（NO）途径的影响。
纳入47例接受经皮CO疗法的高血压患者。招募30名健康个体作为对照组。在首次CO治疗前1小时以及治疗后1小时、24小时和3周采集血样。对照组未接受CO治疗。采用酶联免疫吸附测定法（ELISA）测量血浆ADMA水平。
与基线浓度相比，首次CO₂治疗后1小时ADMA水平显著降低（p = 0.003）。在服用血管紧张素转换酶抑制剂（ACEIs）的患者中发现下降幅度明显更大（p = 0.019）。
ADMA水平的短期和长期下降表明，CO不仅是一种血管扩张剂，而且对NO途径有有益作用。ACE抑制似乎增强了CO治疗的效果。
